Overview

Effects of DPP4 Inhibition on COVID-19

Status:
Withdrawn

Trial end date:
2021-12-30

Target enrollment:

Participant gender:

Summary

The purpose of this research is to see if the DPP4 inhibitor linagliptin, an oral medication commonly used to treat type 2 diabetes,can help with diabetes control and reduce the severity of the COVID-19 infection

Phase:

Phase 4

Details

Lead Sponsor:

University of Miami

Treatments:

Insulin
Insulin, Globin Zinc
Linagliptin